Selective amino acid formulation enhances anion secretion and restores function in cystic fibrosis mutations
IntroductionIn cystic fibrosis (CF), most CFTR mutations cause partial (Class II) or complete (Class I) loss of function. Modulators (VX) can improve CFTR function in Class II mutations but are ineffective for Class I mutations and may cause side effects, resulting in tolerability issues with concer...
Saved in:
| Main Authors: | Astrid Grosche, Anusree Sasidharan, Matthias Salathe, Nathalie Baumlin, Damiano Angoli, Sreekala Prabhakaran, Xiaodong Xu, Sadasivan Vidyasagar |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1522130/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cystic Fibrosis and Reproductive Outcomes: The Latest Insights into Fertility and Pregnancy
by: Weronika Małagocka, et al.
Published: (2025-01-01) -
The enigmatic SLC26A6 multifunctional anion transporter: recent advances in structure-function relationship, pathophysiological significance and novel pharmacological inhibitors
by: Ursula E. Seidler
Published: (2025-01-01) -
A descriptive cohort study of pregnancy and parenthood in women with cystic fibrosis
by: Aleksandra Duffy, et al.
Published: (2025-07-01) -
Analysis of Ivacaftor drug approval for cystic fibrosis patients with gating mutations.
by: Nemirajaiah, S.
Published: (2021-08-01) -
Antenatally diagnosed congenital chloride diarrhea with a de novo mutation: The first reported case from Azerbaijan
by: Sarkhan Elbayiyev, et al.
Published: (2024-09-01)